| Adam H Adler, MD | |
|
1292 Waianuenue Ave, Hilo, HI 96720-1228 | |
| (808) 934-4000 | |
| Not Available |
| Full Name | Adam H Adler |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 1292 Waianuenue Ave, Hilo, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053568923 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | LL17702 (Oregon) | Secondary |
| 207Q00000X | Family Medicine | MD-15715 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hilo Medical Center | Hilo, HI | Hospital |
| Kau Hospital | Pahala, HI | Hospital |
| North Hawaii Community Hospital | Kamuela, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Quantum Healthcare Medical Associates Inc | 5294647574 | 93 |
News Archive
"The most important new antidiscrimination law in two decades — the Genetic Information Nondiscrimination Act — will take effect in the nation's workplaces next weekend, prohibiting employers from requesting genetic testing or considering someone's genetic background in hiring, firing or promotions," The New York Times reports.
The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand many cardiac problems, the data may aid the development of new tools to detect drugs that can have dangerous effects on the heart.
The U.S. Food and Drug Administration has approved the first generic versions of Topamax tablets (topiramate) to prevent seizures.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
While there have been advances in the treatment of hormone-driven breast cancer, resistance to these therapies remains a significant problem.
› Verified 9 days ago
| Entity Name | Quantum Healthcare Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568490597 PECOS PAC ID: 5294647574 Enrollment ID: O20070315000063 |
News Archive
"The most important new antidiscrimination law in two decades — the Genetic Information Nondiscrimination Act — will take effect in the nation's workplaces next weekend, prohibiting employers from requesting genetic testing or considering someone's genetic background in hiring, firing or promotions," The New York Times reports.
The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand many cardiac problems, the data may aid the development of new tools to detect drugs that can have dangerous effects on the heart.
The U.S. Food and Drug Administration has approved the first generic versions of Topamax tablets (topiramate) to prevent seizures.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
While there have been advances in the treatment of hormone-driven breast cancer, resistance to these therapies remains a significant problem.
› Verified 9 days ago
| Entity Name | Hawaii Post Acute Medical Services 1 Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780171074 PECOS PAC ID: 5395093512 Enrollment ID: O20180804000004 |
News Archive
"The most important new antidiscrimination law in two decades — the Genetic Information Nondiscrimination Act — will take effect in the nation's workplaces next weekend, prohibiting employers from requesting genetic testing or considering someone's genetic background in hiring, firing or promotions," The New York Times reports.
The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand many cardiac problems, the data may aid the development of new tools to detect drugs that can have dangerous effects on the heart.
The U.S. Food and Drug Administration has approved the first generic versions of Topamax tablets (topiramate) to prevent seizures.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
While there have been advances in the treatment of hormone-driven breast cancer, resistance to these therapies remains a significant problem.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam H Adler, MD 1292 Waianuenue Ave, Hilo, HI 96720-1228 Ph: (808) 934-4000 | Adam H Adler, MD 1292 Waianuenue Ave, Hilo, HI 96720-1228 Ph: (808) 934-4000 |
News Archive
"The most important new antidiscrimination law in two decades — the Genetic Information Nondiscrimination Act — will take effect in the nation's workplaces next weekend, prohibiting employers from requesting genetic testing or considering someone's genetic background in hiring, firing or promotions," The New York Times reports.
The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand many cardiac problems, the data may aid the development of new tools to detect drugs that can have dangerous effects on the heart.
The U.S. Food and Drug Administration has approved the first generic versions of Topamax tablets (topiramate) to prevent seizures.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
While there have been advances in the treatment of hormone-driven breast cancer, resistance to these therapies remains a significant problem.
› Verified 9 days ago
Jesse C. Maag, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1292 Waianuenue Ave, Hilo, HI 96720 Phone: 808-934-4000 | |
Melanie R Arakaki, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 670 Ponahawai St, Ste 216 Hilo Family Medicine, Hilo, HI 96720 Phone: 808-934-8989 Fax: 808-934-8990 | |
Hamed Ahmadinia, M.D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 45 Mohouli St Ste 201, Hilo, HI 96720 Phone: 808-932-3186 | |
Mr. Gaku Yamaguchi, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1438 Kilauea Ave, Hilo, HI 96720 Phone: 808-969-9220 | |
Timothy S Duerler, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Puuhonu Pl, Ste 205, Hilo, HI 96720 Phone: 808-933-2399 | |
Dr. Andrew Chang, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1190 Waianuenue Ave, Hilo, HI 96720 Phone: 808-932-4215 |